Hantavirus Pulmonary Syndrome

2 claims checked

HEALTH May 8, 2026

Pfizer listed hantavirus pulmonary syndrome on BNT162b2 AESI surveillance lists.

Claim: Pfizer Inc. listed hantavirus pulmonary syndrome as a potential adverse event of special interest (AESI) or possible side effect in its COVID-19 vaccine safety monitoring documents for the BNT162b2 (Comirnaty) vaccine. HARDLY BS

HEALTH May 7, 2026

U.S. Hantavirus Pulmonary Syndrome case-fatality is roughly mid-to-high 30%.

Claim: As of May 7, 2026, the case-fatality rate of Hantavirus Pulmonary Syndrome in the United States is about 35%. HARDLY BS